

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Henrik CLAUSEN and Margarida AMADO

Application No.: 10/777,828

Confirmation No: 5885

Filed: February 12, 2004

Art Unit: 1652

For: UDP-GALACTOSE:BETA-N-ACETYL-
GLUCOSAMINE BETA-1,3-
GALACTOSYLTRANSFERASES, BETA-
3GAL-T5

Examiner: Manjunath N. RAO

**AMENDMENT IN RESPONSE TO ADVISORY ACTION AND ACCOMPANYING
REQUEST FOR CONTINUED EXAMINATION**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Advisory Action of June 4, 2007 and the Office Action of January 17, 2007, please consider the following amendments and remarks and accompanying Request for Continued Examination (RCE). This Response and RCE are accompanying by the required RCE fee under 37 CFR 1.17(e), a Petition for Extension of Time Within the Third Month (the Response to Final Office Action was filed with a Petition for Extension of Time Within the First Month and its accompanying fee) and its required fee under 37 CFR 1.17(a)(2), and a Terminal Disclaimer. The Terminal Disclaimer fee under 37 CFR 1.20(d) is not being paid, as it was paid on May 4, 2007 along with a Terminal Disclaimer that was subsequently found to be defective and not approved.

It is believed that no fee(s) is required for these submissions other than the fees for Extension of Time Within the Third Month and Request for Continued Examination. However,

should the U.S. Patent and Trademark Office determine that any other fee(s) is due or that any refund is owed for this application, the Commissioner is hereby authorized and requested to charge the required fee(s) and/or credit the refund(s) owed to our Deposit Account No. 04-0100.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 4 of this paper.